Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ 333369 as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study: Open-Label Extension Period
NCT00991757 is registered in ClinicalTrials.gov with SK Life Science, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ 333369 as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study: Open-Label Extension Period
- Lead sponsor
- SK Life Science, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 28, 2007
- Completion date
- October 31, 2010
- Enrollment
- 991 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
complex partial seizures, epilepsies, partial, epilepsy, epilepsy, complex partial